Topics

Clinical Outcomes for Deep Brain Stimulation

2019-06-26 04:31:15 | BioPortfolio

Summary

The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.

Study Design

Conditions

Parkinson Disease

Intervention

Deep Brain Stimulation

Location

Washington University in St Louis
Saint Louis
Missouri
United States
63110

Status

Recruiting

Source

Washington University School of Medicine

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-06-26T04:31:15-0400

Clinical Trials [4630 Associated Clinical Trials listed on BioPortfolio]

Effects of Deep Brain Stimulation in Parkinson's Disease

The purpose of this study is to identify factors predicting good results in patients treated with deep brain stimulation for Parkinson's disease. The study includes a comparison of two sur...

Deep Brain Stimulation for Parkinson's Disease Trial

The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatri...

Effect of Deep Brain Stimulation on Depression and Quality of Life in Parkinson’s Patients

We will evaluate the effect of deep brain stimulation on the depression and quality of life in Parkinson’s disease. We aim to compare depression pre-operatively and post-operatively in ...

Flexible vs. Standard Deep Brain Stimulation Programming in Parkinson Disease Patients

Exploring the benefits of the linear lead in deep brain stimulation.

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

The purpose of this study is to evaluate the safety and effectiveness of deep brain stimulation of the nucleus basalis of Meynert (also called the "nbM") at improving memory in Parkinson's...

PubMed Articles [24873 Associated PubMed Articles listed on BioPortfolio]

Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study.

The impact of deep brain stimulation (DBS) on cognitive and urinary disorders, falls, and eventually hospitalizations and mortality in Parkinson's disease (PD) is still debated.

Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation.

Motor dysfunctions in Parkinson disease (PD) patients are not completely normalized by deep brain stimulation (DBS), and there is an obvious difference in the degree of symptom improvement after DBS f...

Interleaving stimulation in Parkinson's disease: interesting to whom?

Interleaving stimulation (ILS) is an available stimulation strategy that can help the physician manage more challenging cases of patients with deep brain stimulation (DBS) for Parkinson's disease. (PD...

Clinical Validation of Quality Improvements Using the Six Sigma Concept: A Case Study for Deep Brain Stimulation in Parkinson's Disease.

The Six Sigma concept allows for the evaluation of quality changes after the implementation of new technical equipment or adjustment of perioperative procedures. Exemplarily, we applied this method fo...

Deep Brain Stimulation Generator Replacement in End Stage Parkinson's Disease.

The decision to replace deep brain stimulation (DBS) generators in end-stage Parkinson's disease is based on the patients' clinical status, as well as the risks of this surgery. The infection rates of...

Medical and Biotech [MESH] Definitions

Therapy for MOVEMENT DISORDERS, especially PARKINSON DISEASE, that applies electricity via stereotactic implantation of ELECTRODES in specific areas of the BRAIN such as the THALAMUS. The electrodes are attached to a neurostimulator placed subcutaneously.

Stimulation of the brain, which is self-administered. The stimulation may result in negative or positive reinforcement.

Proteins associated with sporadic or familial cases of PARKINSON DISEASE.

A condition caused by the neurotoxin MPTP which causes selective destruction of nigrostriatal dopaminergic neurons. Clinical features include irreversible parkinsonian signs including rigidity and bradykinesia (PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al., Principles of Neurology, 6th ed, p1072; Neurology 1986 Feb;36(2):250-8)

A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

More From BioPortfolio on "Clinical Outcomes for Deep Brain Stimulation"

Quick Search

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Searches Linking to this Trial